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IMPORTANCE Hypothermia for 72 hours at 33.5°C for neonatal hypoxic-ischemic
encephalopathy reduces death or disability, but rates continue to be high.
OBJECTIVE To determine if cooling for 120 hours or to a temperature of 32.0°C reduces death
or disability at age 18months in infants with hypoxic-ischemic encephalopathy.
DESIGN, SETTING, AND PARTICIPANTS Randomized 2 × 2 factorial clinical trial in neonates
(36weeks’ gestation) with hypoxic-ischemic encephalopathy at 18 US centers in the Eunice
Kennedy Shriver National Institute of Child Health and Human Development Neonatal
Research Network between October 2010 and January 2016.
INTERVENTIONS A total of 364 neonates were randomly assigned to 4 hypothermia groups:
33.5°C for 72 hours (n = 95), 32.0°C for 72 hours (n = 90), 33.5°C for 120 hours (n = 96), or
32.0°C for 120 hours (n = 83).
MAIN OUTCOMES ANDMEASURES The primary outcomewas death ormoderate or severe
disability at 18 to 22months of age adjusted for center and level of encephalopathy. Severe
disability included any of Bayley Scales of Infant Development III cognitive score less than 70,
Gross Motor Function Classification System (GMFCS) level of 3 to 5, or blindness or hearing
loss despite amplification. Moderate disability was defined as a cognitive score of 70 to 84
and either GMFCS level 2, active seizures, or hearing with amplification.
RESULTS The trial was stopped for safety and futility in November 2013 after 364 of the
planned 726 infants were enrolled. Among 347 infants (95%) with primary outcome data
(mean age at follow-up, 20.7 [SD, 3.5] months; 42% female), death or disability occurred in
56 of 176 (31.8%) cooled for 72 hours and 54 of 171 (31.6%) cooled for 120 hours (adjusted risk
ratio, 0.92 [95% CI, 0.68-1.25]; adjusted absolute risk difference, −1.0% [95% CI, −10.2% to
8.1%]) and in 59 of 185 (31.9%) cooled to 33.5°C and 51 of 162 (31.5%) cooled to 32.0°C
(adjusted risk ratio, 0.92 [95% CI, 0.68-1.26]; adjusted absolute risk difference, −3.1% [95%
CI, −12.3% to 6.1%]). A significant interaction between longer and deeper cooling was
observed (P = .048), with primary outcome rates of 29.3% at 33.5°C for 72 hours, 34.5% at
32.0°C for 72 hours, 34.4% at 33.5°C for 120 hours, and 28.2% at 32.0°C for 120 hours.
CONCLUSIONS AND RELEVANCE Among term neonates withmoderate or severe
hypoxic-ischemic encephalopathy, cooling for longer than 72 hours, cooling to lower than
33.5°C, or both did not reduce death or moderate or severe disability at 18months of age.
However, the trial may be underpowered, and an interaction was found between longer and
deeper cooling. These results support the current regimen of cooling for 72 hours at 33.5°C.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01192776
JAMA. 2017;318(1):57-67. doi:10.1001/jama.2017.7218
Supplemental content
Author Affiliations:Author
affiliations are listed at the end of this
article.
Group Information: The Eunice
Kennedy Shriver National Institute of
Child Health and Human
Development Neonatal Research
Network members are listed at the
end of this article.
Corresponding Author: Seetha
Shankaran, MD, Children’s Hospital of
Michigan, 3901 Beaubien Blvd,
Detroit, MI 48201 (sshankar@med
.wayne.edu).
Research
JAMA | Original Investigation
(Reprinted) 57
© 2017 American Medical Association. All rights reserved.
Downloaded From:  by a Indiana University School of Medicine User  on 01/26/2018
H ypothermia at 33.5°C for 72 hours initiated within 6hours of birth among neonates born at full termwithevidenceofmoderate or severehypoxic-ischemic en-
cephalopathy has reduced the rates of death or survival with
disability in infancy1,2 andchildhood.3,4Data fromanimal stud-
ies published 10 years after the initial clinical neuroprotec-
tion trials1,2 demonstrated that cooling to a depth of 32.0°Cor
for aduration longer than72hours is neuroprotective.5,6 In an
attempt to further decrease the rate of death or disability as-
sociated with hypoxic-ischemic encephalopathy, the current
randomized clinical trial was designed to test whether longer
cooling (120 hours), deeper cooling (32.0°C), or both de-
creases death or disability at 18months of age comparedwith
coolingat33.5°C for72hours.Aprevious report fromthis study
included 4 secondary outcomes (neonatal intensive care unit
[NICU] deaths, acute adverse events, multiorgan dysfunc-
tion, and NICU length of stay).7 This article reports the pri-
mary outcomes of death or disability (moderate or severe) at
age 18 to 22 months.
Methods
The study was conducted at all 18 US sites in the Eunice
Kennedy Shriver National Institute of Child Health and Hu-
man Development (NICHD) Multicenter Neonatal Research
Network between October 2010 and January 2016, with RTI
International as the data coordinating center. Criteria for eli-
gibility and details of cooling and rewarming were similar to
the first NICHD randomized clinical trial of therapeutic
hypothermia1 and published previously.7 Random assign-
ment was stratified by center and level of encephalopathy
(moderate or severe) in a 2 × 2 factorial design to 33.5°C or
32.0°C and to 72hours or 120hours. Neonateswhowere born
at 36 weeks’ or greater gestation were enrolled. The trial pro-
tocol is available in Supplement 1 . An independent data and
safety monitoring committee monitored interim data and
evaluated safety.
The protocol was approved by the institutional review
boardateachsite.Written informedconsentwasobtainedfrom
parents of study participants.
Outcomes
The primary outcome was death or moderate or severe dis-
ability at 18 to 22months of age. This composite outcomewas
selected because death is a competing outcome for disability.
Infants were evaluated at 18 to 22months of age; the families
of those who did not return for follow-up were contacted by
telephone to obtain information about the primary outcome.
Data on growth, vision, and hearing were obtained, and neu-
rological anddevelopmental testingwasperformedby trained
examiners who were masked to intervention status.
Neuromotor disabilitywas based on the presence of cere-
bral palsy, and functional disability was graded according to
the GrossMotor Function Classification System (GMFCS, lev-
els 1-5; level 1 includes children who walk but gait is not flu-
ent; level 2 includes thosewhoareunable towalkbutwhocan
pull to stand and take steps holding on to furniture; level 3 in-
cludes thosewhousehands for sitting support andareunable
to crawl, level 4 includes those for whom support is needed
for sitting; and level 5 includes thosewho require adult assis-
tance to move).8 Cognitive outcome was assessed by the
Bayley Scales of Infant Development III (reported mean, 100
[SD, 15]).9 Severe disability was defined as any of the follow-
ing: a Bayley III cognitive score of less than 70, a GMFCS level
of 3 to 5, blindness, or profound hearing loss (inability to un-
derstandcommandsdespiteamplification).Moderatedisabil-
ity was defined as a Bayley III cognitive score of 70 to 84 and
either aGMFCS level of 2, seizuredisorder, or ahearingdeficit
requiring amplification to understand commands. Mild dis-
ability was defined as a cognitive score of 70 to 84, or a cog-
nitive score of 85 or higher and any of the following: presence
of a GMFCS level 1 or 2, seizure disorder, or hearing loss not
requiringamplification.Normalneurocognitivestatuswasde-
fined as a cognitive score of 85 or higher in the absence of any
neurosensory deficits or seizures after NICU discharge.
Prespecifiedsecondaryoutcomesinthisreport includepost-
NICUdischargemortality; levelofdisabilitybystageofencepha-
lopathy; rates of vision, hearing, andmultiple disabilities; cog-
nitive andmotor scores; cerebral palsy rates; rehospitalization
rates;andgrowthmeasurements.Neonatalbrainmagnetic reso-
nance imaging findingswill be reported separately.
Statistical Analysis
Asamplesizeof726neonates (363 ineachgrouptocompare the
2durationsof coolingandthe2depthsof cooling)wasbasedon
a2-tailedα=.05, a statistical power of 80%, a 5% loss to follow-
up, and a comparison of death or disability of 37.5%and 27.5%
in the2durationsanddepth-of-coolinggroups.Generalizedes-
timating equation (GEE)modelswith log linkwere used to ob-
tain relative risk (RR) estimates for binary outcomes, adjusting
for level of encephalopathy and intracenter correlations. Con-
tinuous outcomeswere similarly assessedusingGEE linear re-
gression after log transformation. Treatment interactions be-
tween the 2 factors (deeper and longer cooling) were assessed
for the primary outcome and key secondary outcomes. All re-
portedPvalues are 2-sided andnot adjusted formultiple com-
parisons. P<.05was considered statistically significant.
Key Points
Question Is cooling for 120 hours, cooling to 32.0°C, or bothmore
neuroprotective than cooling for 72 hours at 33.5°C, the current
standard of care, among neonates with moderate or severe
hypoxic-ischemic encephalopathy at birth?
Findings In this randomized clinical trial that included 364
neonates, there was no significant difference in the probability of
death or disability at 18months of age comparing cooling at 120
hours (31.6%) vs 72 hours (31.8%) or to a depth of 32.0°C (31.5%)
vs 33.5°C (31.9%).
Meaning These findingsdonot support change fromthe current
regimenof cooling for 72hours at 33.5°C for neonateswithmoderate
or severe encephalopathy; however, statistical interactionsbetween
duration anddepthof cooling support thepossibility of higher
mortalitywith the combinationof longer anddeeper cooling,
suggesting that further investigationmaybewarranted.
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Toobtain probability estimates of treatment effect for the
3 experimental groups, aBayesian analysis of deathordisabil-
ity or death alone was conducted. A log binomial model with
level of encephalopathy andmain effects of cooling duration
and depth and their interaction was used to estimate poste-
rior median of the RRs and 95% credible intervals (CrIs). The
model also included a random center effect and used neutral
priors for treatment effects centered at an RR of 1 (95% prior
interval, 0.5-2.0).10 Weakly informative priors were used for
all otherparameters toexclude large treatmenteffects andpro-
duce conservative estimatesof treatment effects (see eAppen-
dix in Supplement 2 for details). The statistical software used
was SAS, version 9.3 (SAS Institute Inc).
Results
The trial was closed for in-hospitalmortality and futility con-
cerns by the data safety andmonitoring committee after 1261
neonates had been screened, 514 were eligible, and 364were
enrolled (Figure).7 At 18 to 22months of age, the primary out-
comewas available for 176 infants in the 72-hour group, 171 in
the 120-hour group, 185 in the 33.5°C group, and 162 in the
32.0°C group. The baselinematernal and neonatal character-
istics of the 72-hour and 120-hour groups and the 33.5°C and
32.0°C groups are shown in Table 1 and those across all 4 ran-
domization groups are presented in the eTable in Supplement
Figure. Flow of Neonates Through a Trial of Cooling for 120Hours vs 72 Hours and Cooling to 32.0°C vs 33.5°C for Hypoxic-Ischemic Encephalopathy
1261 Neonates assessed for eligibility
897 Excluded
747 Did not meet eligibility criteria
36 Chromosomal or congenital anomaly
4 Birth weight <1800 g
18 Unlikely to survive
43 Did not have pH <7.0 or base
deficit >16 mmol/L
293 Did not have moderate or severe
encephalopathya
73 Met no inclusion criteria
58 History of perinatal event but no
birth resuscitation
75 No neurological examination
100 Parents did not consent
5 Physicians refused consent
45 Consent not requested
52 Low core temperature
(<32.5°C for ≥2 h)
95 Aged >6 h
364 Randomized
96 Randomized to 120 h of cooling
at 33.5°C
85 Completed cooling period
at target temperature
11 Did not complete treatment
3 Received ECMO
2 Deaths
3 Withdrawal of life support
3 Other reasons
90 Randomized to 72 h of cooling
at 32.0°C
79 Completed cooling period
at target temperature
11 Did not complete treatment
4 Received ECMO
2 Physician decision to stop
intervention
2 Deaths
1 Withdrawal of life support
2 Other reasons
95 Randomized to 72 h of cooling
at 33.5°C
87 Completed cooling period
at target temperature
8 Did not complete treatment
4 Received ECMO
2 Physician decision to stop
intervention
1 Withdrawal of life support
1 Other reasons
83 Randomized to 120 h of cooling
at 32.0°C
60 Completed cooling period
at target temperature
23 Did not complete treatment
9 Received ECMO
2 Physician decision to stop
intervention
1 Death
3 Withdrawal of life support
2 Do not resuscitate orders
2 Serious adverse events
1 Parental withdrawal of
consent
3 Other reasons
93 Included in primary analysis
3 Excluded (lost to follow-up)
84 Included in primary analysis
6 Excluded (lost to follow-up)
92 Included in primary analysis
3 Excluded (lost to follow-up)
78 Included in primary analysis
5 Excluded (lost to follow-up)
3 Lost to follow-up6 Lost to follow-up3 Lost to follow-up 5 Lost to follow-up
ECMO indicates extracorporeal membrane oxygenation.
a Moderate or severe encephalopathy was defined as the presence of 1 or more
signs in at least 3 of the following 6 categories: (1) level of consciousness
(moderate is lethargic, severe is stupor or coma); (2) spontaneous activity
(moderate is decreased activity, severe is no activity); (3) posture (moderate is
distal flexion or complete extension, severe is decerebrate); (4) tone
(moderate is hypotonia, severe is flaccid); (5) primitive reflexes (moderate is a
weak suck, severe is an absent suck, or moderate is incomplete Moro reflex
and severe is absent); and (6) autonomic nervous system—either pupil
(moderate is constricted; severe is deviated, dilated, or nonreactive to light),
heart rate (moderate is bradycardia, severe is variable heart rate), or
respiration (moderate is periodic breathing, severe is apnea).
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2. The primary outcome of death or moderate or severe dis-
ability occurred in 56 of 176 infants (31.8%) in the 72-hour
group, 54 of 171 infants (31.6%) in the 120-hour group, 59 of
185 infants (31.9%) in the 33.5°C group, and 51 of 162 infants
(31.5%) in the 32.0°Cgroup (Table 2). The adjustedRRs for the
primaryoutcome fordurationordepthof coolingwerenot sig-
nificantly different. The primary outcomewas similar among
infantswithmoderate or severe encephalopathybetween the
120-hour and 72-hour groups and between the 32.0°C and
33.5°C groups.
Most of the secondary outcomes did not differ by dura-
tionordepthof cooling,with theexceptionofmoredeathsbut
fewer rehospitalizations after discharge and infantswithmo-
tor scores less than 70 with duration of cooling of 120 hours
vs 72 hours (Table 2). Very few surviving infants had moder-
ate disability. An interaction test between depth and dura-
tion of cooling in this 2 × 2 factorial design trial was statisti-
cally significant for the primary outcome (P = .048). Rates of
theprimaryoutcomes in the4groupswere 29.3% (27of 92 in-
fants) in the group with 33.5°C for 72 hours, 34.5% (29 of 84
infants) in the groupwith 32.0°C for 72 hours, 34.4% (32 of 93
infants) in the groupwith 33.5°C for 120hours, and 28.2% (22
of 78 infants) in the groupwith 32.0°C for 120hours (Table 3).
The Bayesian analyses of the posterior probabilities of reduc-
ing death or moderate or severe disability with deeper cool-
ing, longer cooling, or both compared with standard cooling
(probability of RR <1.0) were 58%, 50%, and 78%, respec-
tively.Therewasnostatisticallysignificant interactionfordeath
(P = .11) or any other secondary outcome other than a Bayley
III cognitive score of 70 to 84 vs 85 or higher (P = .049) and a
Bayley IIImotor score of less than 70vs 85 or higher (P = .04).
Themortality rates in the4hypothermia groups arenoted
in the eFigure in Supplement 2. TheadjustedRR fordeathwas
higher in thegroupwith33.5°C for 120hoursvs thegroupwith
33.5°C for 72hours (RR, 2.52; 95%CI, 1.06-5.95) (Table 3). The
Bayesian estimates of the adjusted RRs formortality for the 3
interventiongroupscomparedwithstandardcoolingwere 1.08
(95%CrI,0.74-1.59) for thegroupwith32.0°C for 72hours, 1.33
Table 1. Maternal and Neonatal Characteristics for the Duration of Cooling and Depth of Cooling Groupsa
Characteristics
Duration of Cooling Depth of Cooling
72 h
(n = 176)
120 h
(n = 171)
33.5°C
(n = 185)
32.0°C
(n = 162)
Maternal characteristics
Race, No. (%)b
Black 51 (29) 56 (33) 58 (32) 49 (31)
White 113 (65) 98 (58) 112 (61) 99 (62)
Otherb 11 (6) 14 (8) 13 (7) 12 (8)
Age, mean (SD), y 28.1 (6.6) 28.1 (7.0) 28.3 (6.6) 27.9 (7.0)
Married, No. (%) 93 (53) 89 (52) 100 (55) 82 (51)
Gravida, median (IQR) 2 (1-3) 2 (1-3) 2 (1-3) 2 (1-3)
Parity, median (IQR) 1 (1-3) 1 (1-3) 1 (1-3) 1 (1-2)
Pregnancy complications, No. (%)
Chronic hypertension 37 (21) 33 (20) 33 (18) 37 (23)
Antepartum hemorrhage 22 (13) 16 (9) 20 (11) 18 (11)
Thyroid dysfunction 11 (6) 3 (2) 6 (3) 8 (5)
Diabetes 21 (12) 24 (14) 22 (12) 23 (14)
Intrapartum complications, No. (%)
Decelerations in fetal heart rate 134 (77) 134 (79) 144 (79) 124 (77)
Cord prolapse, rupture, or compression 26 (15) 20 (12) 28 (15) 18 (11)
Uterine rupture 11 (6) 11 (6) 9 (5) 13 (8)
Maternal pyrexia (≥37.6°C) 23 (13) 18 (11) 17 (9) 24 (15)
Shoulder dystocia 14 (8) 14 (8) 14 (8) 14 (9)
Maternal hemorrhage 25 (14) 28 (16) 29 (16) 24 (15)
Rupture of membranes (spontaneous or induced),
No. (%)
None 44 (26) 49 (30) 55 (31) 38 (25)
≤18 h prior to delivery 111 (65) 94 (58) 108 (60) 97 (63)
>18 h prior to delivery 16 (9) 20 (12) 17 (9) 19 (12)
Rupture of membranes, h prior to delivery
Mean (SD) 11.1 (19.6) 10.8 (16.8) 10.9 (16.5) 11.0 (20.0)
Median (IQR) 7.6 (2.7-14.7) 5.9 (2.1-14.3) 6.4 (2.3-14.1) 7.3 (1.8-15.1)
Emergency cesarean delivery, No. (%) 111 (63) 107 (63) 113 (61) 105 (65)
(continued)
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(95% CrI, 0.91-1.93) for the group with 33.5°C for 120 hours,
and 1.36 (95%CrI, 0.81-2.21) for the groupwith 32.0°C for 120
hours. The posterior probabilities of increasing death with
deeper cooling, longer cooling, or both compared with stan-
dard cooling (probability ofRR>1.0)were66%,93%, and89%,
respectively.
Discussion
This trial demonstrated that neither longer nor deeper cool-
ingreducedmortalityorappearedneuroprotective in termneo-
nateswithmoderateor severehypoxic-ischemicencephalopa-
thy. The rates of death ormoderate or severe disability among
infants randomized to the usual care group (cooling to 33.5°C
for 72 hours) was 29%; this is lower than the rate of 44% from
the cooled group in the first NICHD Neonatal Research Net-
work cooling trial1 and in other trials.2 This lower ratemay re-
flect the lower rateof severeencephalopathy, loweracuity, and
earlier initiation of cooling in this trial.
In this study, therewasahighermortality ratenotedamong
infants who underwent cooling for 120 hours comparedwith
72hours.The infantsundergoingcoolingfor 120hoursat32.0°C
had thehighestmortality ratesbut lowestdisability rates. This
findingneeds tobe interpretedwithcaution inviewof thecom-
posite outcome, the early closure of the study, and the signifi-
cant interaction between depth and duration of cooling. The
Bayesian analyses indicated a 78%probability that longer and
deeper cooling reduces death or disability; however, this low
disability rate (11%)wasoffsetby the increasedmortality. Some
earlierpreclinical studiesdemonstrated that extending thedu-
rationordepthof coolingwasneuroprotective5,6; other recent
studies have not.11-13
The strengths of this study are that 71% of eligible infants
wereenrolledandprimaryoutcomedatawereavailable for95%
of infants. Functional and cognitive outcome was evaluated
by certified examiners unaware of treatment status. The limi-
tations of this study are that the studywasnot powered to ex-
amine interactions and no adjustments were made for mul-
tiple comparisons.
Table 1. Maternal and Neonatal Characteristics for the Duration of Cooling and Depth of Cooling Groupsa (continued)
Characteristics
Duration of Cooling Depth of Cooling
72 h
(n = 176)
120 h
(n = 171)
33.5°C
(n = 185)
32.0°C
(n = 162)
Neonatal characteristics
Age at randomization, mean (SD), h 5.0 (1.1) 4.9 (1.4) 4.9 (1.1) 4.9 (1.4)
Transferred from birth hospital, No. (%) 114 (65) 111 (65) 121 (65) 104 (64)
Male, No. (%) 102 (58) 100 (58) 99 (54) 103 (64)
Apgar score ≤5, No. (%)
5 min after birth 147 (84) 143 (85) 157 (85) 133 (83)
10 min after birth 102 (66) 109 (71) 111 (70) 100 (67)
Birth weight, mean (SD), g 3300 (530) 3429 (649) 3297 (610) 3440 (567)
Gestational age, mean (SD), wk 38.6 (1.5) 38.7 (1.4) 38.5 (1.4) 38.7 (1.5)
Length, mean (SD), cm 50.6 (2.9) 50.8 (3.1) 50.5 (2.9) 50.9 (3.1)
Head circumference, mean (SD), cm 34.0 (1.9) 34.3 (1.7) 34.0 (1.6) 34.2 (2.0)
Intubation in delivery room, No. (%) 135 (77) 136 (80) 146 (79) 125 (78)
Continued resuscitation at 10 min, No. (%) 149 (85) 152 (90) 163 (89) 138 (86)
Time to spontaneous respiration
>10 min, No. (%)
70 (42) 76 (48) 81 (47) 65 (42)
Cord blood
pH, mean (SD) 6.9 (0.2) 6.9 (0.2) 6.9 (0.2) 7.0 (0.2)
Base deficit, mean (SD), mmol/L 16.0 (7.8) 15.9 (6.6) 16.0 (7.5) 15.9 (6.9)
Seizuresc 46 (26) 56 (33) 57 (31) 45 (28)
Moderate encephalopathyd 135 (77) 128 (75) 146 (79) 117 (72)
Severe encephalopathyd 41 (23) 43 (25) 39 (21) 45 (28)
Inotropic supportc 42 (24) 33 (19) 35 (19) 40 (25)
Anticonvulsantsc 29 (18) 25 (17) 30 (19) 24 (17)
Abbreviation: IQR interquartile range.
a Percentages are based on the number of mothers or neonates for whom data
were available. Because of rounding, not all percentages sum to 100.
bOther race includes American Indian or Alaskan Native, Asian, Native Hawaiian
or other Pacific Islander, andmore than 1 race.
c Data are from time of randomization.
d Encephalopathy was defined as the presence of either moderate or severe
signs in at least 3 of the following 6 categories: (1) level of consciousness
(moderate is lethargic, severe is stupor or coma); (2) spontaneous activity
(moderate is decreased activity, severe is no activity); (3) posture (moderate is
distal flexion or complete extension, severe is decerebrate); (4) tone
(moderate is hypotonia, severe is flaccid); (5) primitive reflexes (moderate is a
weak suck, severe is an absent suck, or moderate is incomplete Moro reflex
and severe is absent); and (6) autonomic nervous system—either pupil
(moderate is constricted; severe is deviated, dilated, or nonreactive to light),
heart rate (moderate is bradycardia, severe is variable heart rate), or
respiration (moderate is periodic breathing, severe is apnea). The number of
moderate or severe signs determined the extent of encephalopathy; if signs
were equally distributed, the designation was based on level of consciousness.
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Conclusions
Amongneonatesofat least36weeks’gestationalagewithmod-
erate or severe hypoxic-ischemic encephalopathy, cooling for
longer than 72 hours, cooling to a depth lower than 33.5°C, or
both did not reduce death or disability at 18 months of age.
However, the trial may be underpowered, and an interaction
was found between longer and deeper cooling. These results
support the current regimen of cooling for 72 hours at 33.5°C.
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